a16z Medical Partner Julie Yoo: Poor Experience at Physical Pharmacies
Andreessen Horowitz General Partner Julie Yoo stated that Amazon Pharmacy was out of stock, prompting her to visit a retail pharmacy for a prescription refill. The 20-minute in-store process reaffirmed her desire to avoid physical pharmacies. She did not specify the exact in-store steps, only describing the duration as "too long." Yoo joined the firm in 2019, focusing on investments in companies related to healthcare access, payment, and experience, with a portfolio that includes AKASA, Alchemy, Ambience, Hippocratic AI, Sprinter Health, and Turquoise Health. Previously, she co-founded Kyruus and served as Chief Product Officer, leading the platform to approximately 20 million patients and 225,000 doctors before its acquisition. She also worked at Generation Health, which was acquired by CVS. In a podcast, she discussed with PillPack co-founder Elliot Cohen, noting that PillPack was founded due to errors in mail-order pharmacy prescriptions and was later acquired by Amazon to form Amazon Pharmacy. She has also invested in Alchemy, which builds pharmacies for safety-net clinics, with a $31 million seed round led by the firm.
In recent years, Amazon Pharmacy has added prescription pickup lockers, Prime membership packages, and GLP-1 delivery: Medicare-eligible individuals can access certain weight loss injections for $50 per month with free shipping, expanding same-day delivery to nearly 4,500 towns; manufacturer coupons reportedly saved over $300 million on prescription drugs. Industry surveys have shown that only about half of customers believe retail stores can quickly fulfill prescriptions. The head of the National Community Pharmacists Association compared stock shortages to a vending machine lacking Snickers, emphasizing that medications must not be out of stock. Yoo has also written that healthcare AI must evolve from intelligence and administrative automation to "accountability": what truly resists model replacement are delivery, in-store services, and products requiring trials and approvals.
Her portfolio and public writings repeatedly highlight investment themes in pharmacy infrastructure, in-clinic fulfillment, and consumer pathways. Stock shortages forced her from a mail-order loop back to the counter, serving as a personal example of the friction in physical stores, rather than an operational report from Amazon Pharmacy.
From a market mechanism perspective, this is an investor experience post, not a pharmacy financial report. The buyer is a digital pharmacy and home delivery service that expresses "never wanting to step into a store again" as product demand, while the seller is the counter time at CVS, Walmart, and independent stores. Capital does not move due to a single post; it still flows based on prescription migration and PBM contracts. Beneficiaries are channels that can maintain stock and deliver to homes, while retail pharmacies relying on in-store traffic face pressure; stock shortages reveal the fragility of delivery commitments: once the warehouse is out of stock, users immediately revert to the 20 minutes she wanted to escape. Amazon seeks Prime prescription stickiness, while retail stores aim for consultations and immediate inventory, both competing for the last mile on the same prescription.
In supplementary remarks, she linked the healthcare consumer experience with the fund's focus on "on-site fulfillment plus accountability," stating that stock shortages merely demonstrated this line in action.
ABAB AI Insight
Yoo used her own prescription to conduct a stress test on retail pharmacies. Stock shortages are not a new incident but rather a boundary of mail-order pharmacy commitments: what Amazon Pharmacy acquired from PillPack was sorting and home delivery, not unlimited SKUs. The 20-minute counter experience transformed her investment theme—reducing patient coordination costs—from a memo into a bodily memory. She invested in Alchemy for safety-net clinics to build their own pharmacies, Turquoise for price transparency, and Sprinter for home delivery, all aiming to eliminate the "trip to the store" from the pathway.
The capital pathway is consumer-level fulfillment replacing counter rent. Amazon uses Prime, lockers, and GLP-1 free shipping to compete for prescriptions; CVS competes for consultations and vaccines through store density. PBM and list prices still sit above both. The fund Yoo is part of bets on AI reducing labor and on-site services forming accountability that models cannot replace. Stock shortages indicate that the fulfillment layer collapses before the model layer: smart recommendations cannot produce medications that are not in stock. Kyruus sells doctor matching, and Generation Health sells medication management, both experiences pointing to "patients should not be their own coordinators."
The analogy is that e-commerce turned department stores into samples of poor reviews, and now department stores are countering with experiential counters. Pharmacies are at a stage where automated dispensing, clinic lockers, and mail-order are all running in parallel. JD Power-style satisfaction metrics provide digital pharmacies with talking points, while community pharmacists use "not a Snickers" to maintain safety narratives. Both are competing for control over the same prescription.
Structural changes belong to technology replacement stuck in inventory. Delivery software can reduce wait times but cannot compress batches and cold chains. The mechanism is: stock shortages bounce users from low-friction channels back to high-friction ones, validating and exposing the investment narrative at that moment—closed loops only exist when there are medications available. The 20-minute counter experience is a product of retail and also serves as customer acquisition advertising for digital pharmacies.
ABAB News · Cognitive Law
- The end of the delivery promise is when that box is not in the warehouse.
- The 20 minutes that investors dislike often represent the profits of old channels.
- Before eliminating the in-store pathway, one must ensure that stock is still in the chain.